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The potential impact of high-intensity focused ultrasound (HIFU) to general medicine and oncology seems very
high. However, while in the research area, the development of this technique is very rapid and unchallenged. The
direct application of HIFU to human tumour therapy is hampered by various technical difficulties, which may
confine its role to a marginal device in the surgery armamentarium. To deploy the full potential of focused
ultrasound in oncology, it seems necessary to review the basic relationship between HIFU and external beam
radiotherapy. This is the aim of the present work.
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Let us introduce a future scenario, involving the integra-
tion of external beam radiotherapy (EBRT) and high-
intensity focused ultrasound (HIFU), with a case history
taken from our collection of bone metastasis treatments
using magnetic resonance-guided high-intensity focused
ultrasound (MRgFUS) [1].
The patient (female, 55 years old, with pelvic metasta-
ses from rectal adenocarcinoma) spent more than 3 h in
the MRI machine undergoing MRgFUS treatment by the
medical team with an Exablate 2100 (InSightec, Tirat
Carmel, Israel [2]) for the pain palliation of a fairly large
pelvic bone metastasis. At that point, there was no rea-
son to continue: the periosteal innervation, the probable
cause of the pain [3,4], had been ablated as well as a
large part of the cancerous metastatic tissue. However,
the whole metastatic tissue was not destroyed for several
reasons: the patient could not endure an even longer
stay in the magnet, a part of the potentially cancerous
tissue was ‘shadowed’ by a compact bone structure, an-
other (smaller) part was very near to the rectum, and
there was no other viable beam direction which would
have allowed the ablation to continue. Sometime after* Correspondence: giovanni.borasi@unimib.it
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reproduction in any medium, provided the orthe treatment, the patient experienced an extraordinary
improvement in his quality of life: the pain almost com-
pletely disappeared. The pain interference scale score [5]
decreased from 6 to 0.6 and the VAS score [6] from 9 to 3.
The patient was no longer bed-bound, and the amount of
opiates prescribed was significantly reduced. Three
months later, by comparing the new fluorodeoxyglucose
(FDG)-PET/CT examination with that done before the
MRgFUS treatment, the images left no doubts. The ab-
lated region did not show any FDG uptake, but where we
were not able to ablate, a considerable, non-painful,
tumour proliferation was evident. At that point, it was
clear to anyone that the best treatment would have been
HIFU plus concurrent radiotherapy.
It can be added that according to current protocols,
HIFU is only employed for palliative treatment of bone
metastases (pain reduction), when the disease has be-
come systemic. In several cases, complete success (pain
palliation and total metastasis ablation) has been
obtained [7]. However, in the above case history, would
there have been a realistic chance for EBRT to have been
effective? Even if the management of bone metastases
requires a multidisciplinary approach [8], the answer is
that local EBRT is probably the treatment of choice for
localised bone pain [9-11]. There is a large body of pub-
lished reports that confirms the efficacy of thistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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treatments. Overall, 70–80% of patients will respond,
and up to one third will achieve a complete response
[12]. The HIFU challenge is to do even better, and there
is increasing evidence in this direction [13-16]. This par-
ticular patient was first proposed for EBRT, but he pre-
ferred HIFU. Therefore, in locations where HIFU was
impossible to administer, EBRT would have been the
best choice. Another way could have been to employ
one of the minimally invasive techniques (like alcohol
injection or LASER, or radio-frequency/microwave abla-
tion or cryotherapy). These techniques are a very im-
portant resource in the management of bone metastases
[9]. In this particular case, due to the lesion dimensions
and the presence of bone and sensitive structures
(rectum, nerves), the above techniques would encounter
severe difficulties in the ablation of the whole of the can-
cerous tissue. EBRT, which can easily penetrate the thick
bone structure, can reach and, hopefully, sterilize each
part of the lesion and even guarantee a safety margin
around the tumour.
HIFU, hyperthermia and radiotherapy
In our opinion, there is no scientific rationale for trials
comparing the palliative effect of MRgFUS versus EBRT
in bone metastasis treatment. In fact, the practicalities of
implementation and the physical and biological mecha-
nisms are totally different. Provided that HIFU can be ad-
ministered (given constraints such as nerves, bowel and
non-targeted bone in the beam path [17]), it directly de-
stroys the periosteal innervation, the probable cause of the
pain [3,4], thereby resulting in a remarkable and enduring
pain reduction [13-16]. On the other hand, in some cases
it cannot eradicate the whole cancerous tissue. Radiation
has fewer constraints and acts by reducing (or eliminating)
the proliferative effect of the tumour. Pain reduction may
result from lowering the pressure of the tumour on the
nerves of endosteum or on nerve roots inside the lesion
[3]. In addition, EBRT can treat larger targets though it
may be less effective in pain palliation. In fact, less than
30% of the patients experience complete pain relief [12],
and also this is frequently temporary with recurrence of
pain in 57% of patients at 15 weeks (median value) after
completion of the treatment [18]. Being highly comple-
mentary, the combination of EBRT and HIFU could, in
many cases, provide the patient with the best possible
treatment. The same may be true for tumours other than
bone metastases.
A key question arises: what is the optimal way to use
HIFU plus EBRT and what is the best timing for
combining them?
Photon EBRT has more than a hundred years of history,
and consequently, a great deal is known about it. Onepoint seems to be clear: when the tumour has become
quite large, the central part is somewhat compressed by
angiogenesis, has a poorer blood supply and tends to be-
come hypoxic. In these conditions, ionizing radiation
loses much of its destructive capability, which relies on a
good oxygen supply [19]. That seems exactly the perfect
target for HIFU, whose effect is not significantly
dependent on the oxygen supply. On the other hand, the
peripheral regions of the tumour, where the oxygen sup-
ply is good but also cell proliferation is high, are
certainly a better target for radiation, and a good
sterilization of quite large volumes may be possible in a
reasonable time. The precise localization of the hypoxic
region inside the tumour, recently obtained with contrast
MR, opens the door to personalized treatments [20].
Also, the optimal timing seems to have a quite simple
rationale: when we treat with HIFU, a lot of heat is pro-
duced and diffuses from the focus toward external tissue
regions, while the temperature progressively decreases.
It is well known that mild hyperthermia (HT) increases
the blood supply which can make ionizing radiation
more effective. A nice example comes from the treat-
ment of primary, locally advanced, cervix cancer,
where the beneficial effect of adding HT to EBRT
(thermoradiotherapy) has been confirmed in a large popu-
lation (378 cases) [21]. Of course, the positive effect of HT
does not stop immediately when the heated tissues return
to the normal body temperature. The effect may last
sometime, depending on several conditions, and this could
explain the good results obtained from combining HIFU
with EBRT, even at intervals of several hours [22]. How-
ever, if we could choose the optimal timing, we would say:
‘EBRT immediately after HIFU’ [23,24]. In this way, the
heat produced by HIFU, in a time of just a few minutes,
would become a powerful enhancer for the concomitant
EBRT. The same heat could also be of fundamental im-
portance if we consider the possibility of heat (mild HT)-
mediated drug delivery [25]. A more complex recent
experiment [26] involved (1) pulsed ultrasound (pFUS),
(2) EBRT, (3) an antitumor drug (Docetaxel) and combi-
nations (1) + (3), (2) + (3) and (1) + (2) + (3) on mice bear-
ing prostate tumours. Quite reasonably, the combination
of all the three weapons gave the best tumour control.
Quite inexplicably, (1) + (2) was not tested. However, con-
sidering here mainly HIFU and EBRT, this strategy would
allow also a great sparing of time and of radiation dose. A
lower radiation level means, in turn, a potentially signifi-
cant reduction of sequelae, as reported in a recent paper
[27]. Of course the scenario described above would require
a great deal of fundamental and experimental research. To
find, for each tumour type, the best combination of HIFU
and EBRT will be as fascinating as that of drug delivery
(and it may be possible to do it in the same environ-
ment). However, by working with cells or small animals,
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EBRT phenomenon could be eventually gained without
new devices and great financial investment. For larger
animals and for humans, however, the problem will be
substantially different. The current designs of ‘total
body’ HIFU systems (both with US and MR guidance),
with an unsealed transducer positioned under the pa-
tient couch, requiring a considerable adaptation of the
patient to the machine, seem more ‘proof of concept’
than mature systems, specifically oriented to intensive
patient cure.
A new weapon
A new generation of total body HIFU systems may rely, in
our opinion, on a sealed phased array transducer, robotic-
ally moved in different (anterior and posterior) regions of
the patient (or, eventually, on multiple transducers). A first
example of this kind is the flat, 1024 piezoelectric element,
phased array transducer named ‘Conformal Bone System’
developed by Insightec [2] for treating bone metastasis.
This ‘Work in Progress’ probe includes a built-in skin
cooling system, based on a water bag and a water-
permeable membrane, providing the acoustic coupling.
The probe is held manually by the clinician and positioned
in different body regions without moving the patient on
the couch. Chinese scientists are also producing sealed
multi-element transducers that can be coupled to the pa-
tient with a water-filled bladder [22]. In the last years,
MR-compatible robots have been developed for MR-
guided surgery [28] and have been modified to move an
HIFU transducer within the MR bore [29,30]. Following
this line of thought, we could have not just better clinical
HIFU systems, but also systems whose integration in an
EBRT environment would be less problematic. A giant
step in the integration of systems that appeared to be in-
compatible was taken by Elekta (Stockholm, Sweden) [31]
with the project of a short 6-MV linear accelerator (linac),
rotating around a modified MR magnet. This environment
would be ideal for integrating also a robotically controlled
HIFU transducer. However, also conventional linacs could
be provided with robotically managed HIFU systems,
using for imaging and temperature control an appropriate
echographic system (eventually integrated in the same
probe). The great progress in this latter field may make
MR guidance non-essential [32-35]. Up to this point, we
have focused on body applications, but we cannot forget
the problem of brain pathology. To the best of the au-
thors' knowledge, the only HIFU equipment currently
available is a dedicated helmet in an MR-guided environ-
ment [36,37]. These kinds of systems are opening up new
avenues in direct tumour ablation [38] or in localized
small-area brain ablation for debilitating pathologies [39].
They are also giving rise to great hopes for localized drug
delivery via brain–blood barrier reversible openings [40].This kind of environment could make direct integration
with EBRT difficult, even if, in principle, the patient could
be moved on the same table between the HIFU helmet
and the EBRT area within the modified MR system we
mentioned above [31]. However, robotically guided short
linacs are currently used for radiosurgical therapy in the
brain [41]. However, even with these highly sophisticated
approaches, treatment sequelae are non-negligible [42].
To enhance the treatment efficacy and lower the risks, this
robotic environment could be improved by including add-
itional arms, carrying the HIFU transducer and, eventu-
ally, an echographic probe. Summarizing, hyperthermia,
eventually generated by ablation, is a potent enhancer of
EBRT. What is lacking is a single integrated system for
concomitant EBRT and HIFU for both the human brain
and body.
Conclusions
The technical and economic difficulties of developing
such a device should not be underestimated. On the
other hand, we could have a potent new weapon against
cancer (and, thanks to drug delivery, also against many
degenerative diseases) integrating, in real time, target
and temperature imaging, radiation sterilization, hyper-
thermia, ablation and drug delivery. In all probability,
this device would be a lot less expensive and, for many
cancer localization, a great deal more effective than ex-
pensive and, therefore, practically inaccessible proton or
heavy ion radiotherapy.
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